April 25 AbbVie Inc reported better
than expected sales and earnings, fueled by soaring sales of its
Humira treatment for rheumatoid arthritis and other prescription
The U.S. drugmaker on Friday said it earned $980 million, or
61 cents per share, in the first quarter. That compared
with $968 million, or 60 cents per share, in the year-ago
Excluding special charges, AbbVie earned 71 cents per share.
Analysts, on average, expected 68 cents per share, according to
Thomson Reuters I/B/E/S.
Global revenues of AbbVie, which was spun off from Abbott
Laboratories Inc early last year, rose 5.4 percent to
$4.56 billion, well above Wall Street forecasts of $4.33
(Reporting by Ransdell Pierson)